ADC Therapeutics is a clinical-stage oncology biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology.
ADCT
1.98 as of 3/27/23
